Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.06
-18.4%
$0.21
$0.06
$1.33
$15.77M2.1855.57 million shs36.90 million shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.57
-2.5%
$0.67
$0.53
$4.41
$24.02M-0.74502,906 shs290,114 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.84
+1.9%
$3.50
$2.57
$6.88
$23.73M0.643,149 shs5,915 shs
Nuvilex Inc. stock logo
PMCB
Nuvilex
$0.89
-0.2%
$1.02
$0.80
$2.42
$6.12M-0.2939,870 shs14,038 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
0.00%-23.23%-78.48%-78.59%-94.28%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
0.00%-1.53%-16.88%-38.60%-66.66%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+3.78%+12.61%+18.15%-26.30%
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.00%+6.87%-13.04%-16.32%-53.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
1.8863 of 5 stars
3.03.00.00.03.00.80.0
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.0914 of 5 stars
3.63.00.00.02.62.50.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.5394 of 5 stars
0.04.00.00.03.31.70.6
Nuvilex Inc. stock logo
PMCB
Nuvilex
1.7268 of 5 stars
0.03.00.00.03.10.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.00
Hold$1.352,171.71% Upside
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.20
Buy$13.002,166.78% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PMCB, FBLG, NAII, and ADAP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $12.00
8/4/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/29/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/29/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/29/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/9/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/17/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.09N/AN/A($0.27) per share-0.22
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.02 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.21N/AN/A$13.32 per share0.29
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/A$3.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.65N/AN/AN/A-260.82%-890.69%-75.83%N/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Nuvilex Inc. stock logo
PMCB
Nuvilex
$330K$2.590.34N/AN/A0.51%0.35%9/15/2025 (Estimated)

Latest PMCB, FBLG, NAII, and ADAP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million
8/8/2025Q4 2025
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/A-$0.25N/A-$2.02N/AN/A
7/31/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.11-$0.12-$0.01-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
1.52
1.79
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
0.93
0.93
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/A
14.21
14.21

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Nuvilex Inc. stock logo
PMCB
Nuvilex
34.24%

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
12.74%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
20.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Nuvilex Inc. stock logo
PMCB
Nuvilex
10.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1041.89 million33.51 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Nuvilex Inc. stock logo
PMCB
Nuvilex
46.80 million6.10 millionOptionable

Recent News About These Companies

MyMD Pharmaceuticals Secures Strategic Investments
PharmaCyte Biotech Inc PMCB
PharmaCyte Biotech Invests In Femasys - Quick Facts
Los Angeles Biotech News
Biotech ETFs’ Performance Deserves A Look
How DFW Becomes a Biotech Hub

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.06 -0.01 (-18.38%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$0.07 +0.01 (+22.18%)
As of 08/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.57 -0.01 (-2.47%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$0.58 +0.00 (+0.44%)
As of 08/15/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.84 +0.07 (+1.86%)
As of 08/15/2025 03:59 PM Eastern

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Nuvilex stock logo

Nuvilex NASDAQ:PMCB

$0.89 0.00 (-0.20%)
Closing price 08/15/2025 03:45 PM Eastern
Extended Trading
$0.90 +0.01 (+1.35%)
As of 08/15/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.